The RMs were divided into three groups (Fig. 1a): (1) 8 animals received a single 50 mg kg−1 dose of the anti-CD8α-depleting antibody, MT807R1, 1 d before SIV infection (Group-1: Pre-infection CD8+ depletion); (2) 8 animals received MT807R1 1 d before ART initiation (Group-2: Pre-ART CD8+ depletion); and (3) 5 animals served as controls (Group-3). The gene discussed is CD8A; the disease is infection.